DOWNINGTOWN, PA — Vytala announced key milestones for Seracal™, its novel medical food formulated to address fat malabsorption, as adoption continues to accelerate nationwide. The company reports monthly sales growth exceeding 30%, driven by clinician demand, patient need, and broad insurance coverage across the United States.
The growth comes alongside expanding clinical research into Seracal’s use among pediatric and adult patients with gastrointestinal disorders. A newly approved Institutional Review Board (IRB) study at Broward Health in South Florida, led by Dr. Debora Duro, Program Director of Pediatric Gastroenterology, Hepatology and Nutrition at Salah Foundation Children’s Hospital, will analyze outcomes in approximately 30 pediatric GI patients treated with Seracal. Results are expected in 2026.
Seracal is based on Lym-X-Sorb®, a fat absorption technology developed by Dr. David Yesair of BioMolecular Products, Inc. The technology has been supported by more than $30 million in research funding, including a $7 million NIH clinical trial that demonstrated significant improvements in body mass index, fat-soluble vitamin absorption, and tolerance in patients with cystic fibrosis and exocrine pancreatic insufficiency.
Vytala holds exclusive global rights to the proprietary Lym-X-Sorb formulation and manufacturing process and has enhanced it for improved taste, palatability, and stability. Clinicians have reported encouraging outcomes in pediatric patients with complex gastrointestinal conditions, including cases of short bowel syndrome where Seracal has supported weight gain and reduced reliance on parenteral nutrition.
In addition to the Broward Health study, a multi-center prospective trial led by Dr. Ireton-Jones is underway to evaluate Seracal’s effectiveness across broader patient populations. The ongoing study is tracking weight gain, growth, and gastrointestinal symptom improvement in patients aged one and older.
As Vytala continues to expand Seracal’s clinical footprint, the company aims to establish the product as a key nutritional therapy for patients with fat malabsorption linked to a range of GI disorders. Seracal is available nationwide and covered by most major healthcare insurers.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.